Biotech · Private company
Imugene Limited
Track this companyFree. Adds Imugene Limited to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- AtezolizumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Azer-celPhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- BlinatumomabPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CF33-CD19 IT CombinationPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CF33-CD19 IT MonotherapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CF33-CD19 IV CombinationPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CF33-CD19 IV MonotherapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CF33-hNISPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- HydroxyureaPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Ibrutinib, Acalabrutinib, Zanubrutinib, or PirtobrutinibPhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- IMU-201 (administered as PD1-Vaxx) - Regimen 1Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMU-201 (administered as PD1-Vaxx) - Regimen 2Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMU-201 (administered as PD1-Vaxx) - Regimen 3Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Modified FOLFOXPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)PHASE1 · TERMINATED · started Oct 2, 2023ClinicalTrials.gov NCT06063317 · fetched Nov 12, 2026
- A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid TumorsPHASE1 · TERMINATED · started May 17, 2022ClinicalTrials.gov NCT05346484 · fetched Nov 12, 2026
- CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 18, 2021ClinicalTrials.gov NCT05081492 · fetched Nov 12, 2026
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerPHASE1 · TERMINATED · started Nov 30, 2020ClinicalTrials.gov NCT04432207 · fetched Nov 12, 2026
- Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical StudyRECRUITING · started Aug 25, 2020ClinicalTrials.gov NCT05822427 · fetched Nov 12, 2026
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE1 · RECRUITING · started Mar 11, 2019ClinicalTrials.gov NCT03666000 · fetched Nov 12, 2026